ES2377785B2 - Composición farmacéutica para el tratamiento del ojo seco. - Google Patents

Composición farmacéutica para el tratamiento del ojo seco. Download PDF

Info

Publication number
ES2377785B2
ES2377785B2 ES201031341A ES201031341A ES2377785B2 ES 2377785 B2 ES2377785 B2 ES 2377785B2 ES 201031341 A ES201031341 A ES 201031341A ES 201031341 A ES201031341 A ES 201031341A ES 2377785 B2 ES2377785 B2 ES 2377785B2
Authority
ES
Spain
Prior art keywords
trpm8
agonist
methyl
isopropyl
mentane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201031341A
Other languages
English (en)
Spanish (es)
Other versions
ES2377785A1 (es
Inventor
Carlos Belmonte Martínez
Juana Gallar Martínez
Antonio Ferrer Montiel
Asia Fernández Carvajal
Félix Viana De La Iglesia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Miguel Hernandez de Elche UMH
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Miguel Hernandez de Elche UMH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201031341A priority Critical patent/ES2377785B2/es
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad Miguel Hernandez de Elche UMH filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to PCT/ES2011/070627 priority patent/WO2012032209A2/es
Priority to EP23183121.5A priority patent/EP4268814A3/en
Priority to EP11823113.3A priority patent/EP2614860A4/en
Priority to US13/821,840 priority patent/US9095609B2/en
Priority to JP2013527651A priority patent/JP2013537887A/ja
Publication of ES2377785A1 publication Critical patent/ES2377785A1/es
Application granted granted Critical
Publication of ES2377785B2 publication Critical patent/ES2377785B2/es
Priority to US14/699,873 priority patent/US9433679B2/en
Priority to US15/227,436 priority patent/US9901549B2/en
Priority to JP2016190040A priority patent/JP2017036298A/ja
Priority to US15/350,938 priority patent/US10028920B2/en
Priority to JP2019094210A priority patent/JP2019131621A/ja
Priority to JP2021068077A priority patent/JP2021107422A/ja
Priority to JP2024039617A priority patent/JP2024069452A/ja
Priority to JP2025143562A priority patent/JP2025172101A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES201031341A 2010-09-08 2010-09-08 Composición farmacéutica para el tratamiento del ojo seco. Active ES2377785B2 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES201031341A ES2377785B2 (es) 2010-09-08 2010-09-08 Composición farmacéutica para el tratamiento del ojo seco.
PCT/ES2011/070627 WO2012032209A2 (es) 2010-09-08 2011-09-08 Composición farmacéutica para el tratamiento del ojo seco
EP23183121.5A EP4268814A3 (en) 2010-09-08 2011-09-08 Pharmaceutical composition for the treatment of dry eye
EP11823113.3A EP2614860A4 (en) 2010-09-08 2011-09-08 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYES
US13/821,840 US9095609B2 (en) 2010-09-08 2011-09-08 Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia
JP2013527651A JP2013537887A (ja) 2010-09-08 2011-09-08 ドライアイの治療用医薬組成物
US14/699,873 US9433679B2 (en) 2010-09-08 2015-04-29 Use of TRMP8 for treating opthalmic diseases or conditions involving tearing
US15/227,436 US9901549B2 (en) 2010-09-08 2016-08-03 Method for treating vaginal dryness by administering transient receptor potential cation channel subfamily M member 8 (TRPM8) receptor agonists
JP2016190040A JP2017036298A (ja) 2010-09-08 2016-09-28 ドライアイの治療用医薬組成物
US15/350,938 US10028920B2 (en) 2010-09-08 2016-11-14 Methods for treating occular irritation involving tearing by administering modulators of TRPM8
JP2019094210A JP2019131621A (ja) 2010-09-08 2019-05-20 ドライアイの治療用医薬組成物
JP2021068077A JP2021107422A (ja) 2010-09-08 2021-04-14 ドライアイの治療用医薬組成物
JP2024039617A JP2024069452A (ja) 2010-09-08 2024-03-14 ドライアイの治療用医薬組成物
JP2025143562A JP2025172101A (ja) 2010-09-08 2025-08-29 ドライアイの治療用医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201031341A ES2377785B2 (es) 2010-09-08 2010-09-08 Composición farmacéutica para el tratamiento del ojo seco.

Publications (2)

Publication Number Publication Date
ES2377785A1 ES2377785A1 (es) 2012-04-02
ES2377785B2 true ES2377785B2 (es) 2012-09-26

Family

ID=45811010

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201031341A Active ES2377785B2 (es) 2010-09-08 2010-09-08 Composición farmacéutica para el tratamiento del ojo seco.

Country Status (5)

Country Link
US (4) US9095609B2 (enExample)
EP (2) EP4268814A3 (enExample)
JP (6) JP2013537887A (enExample)
ES (1) ES2377785B2 (enExample)
WO (1) WO2012032209A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377785B2 (es) * 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
JP6110124B2 (ja) * 2012-04-18 2017-04-05 花王株式会社 運動神経活性化用皮膚塗布剤
CN103040976B (zh) * 2012-12-31 2014-01-15 刘建贞 一种促进面神经损伤外科吻合术后康复的药物
EP3060569B8 (en) * 2013-10-22 2021-11-24 IVIEW Therapeutics, Inc. Di-isopropyl-phosphinoyl-alkane (dapa) compounds as topical agents for the treatment of sensory discomfort
JP6692162B2 (ja) * 2014-01-17 2020-05-13 キッセイ薬品工業株式会社 α−置換グリシンアミド誘導体
US20150290029A1 (en) * 2014-04-11 2015-10-15 Edward Tak Wei Delivery Systems for Agents to treat Ocular Discomfort
MX2017005046A (es) * 2014-10-31 2017-07-04 Avent Inc Metodo y articulos para inhibir las contracciones vesicales.
WO2017062570A1 (en) * 2015-10-06 2017-04-13 Ora, Inc. Transient receptor potential cation channel subfamily m member 8 (trpm8) antagonists and methods of use
EP3184524A1 (en) 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
ES2625393A1 (es) * 2016-01-19 2017-07-19 Universidad Miguel Hernandez De Elche Compuestos agonistas del receptor trpm8 y sus aplicaciones
JP2020531473A (ja) * 2017-08-18 2020-11-05 ザ スケペンス アイ リサーチ インスティテュート，インコーポレイテッド ドライアイの処置のための組成物およびその使用の方法
EP3781175A1 (en) 2018-04-18 2021-02-24 i.com Medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
GB201807305D0 (en) * 2018-05-03 2018-06-20 Nicoventures Trading Ltd Vaporisable formulation
JP6564498B2 (ja) * 2018-06-06 2019-08-21 エドワード タク ウェイＷＥＩ， Ｅｄｗａｒｄ Ｔａｋ 感覚的不快感の治療向け局所薬としてのジ−イソプロピル−アルカン（ｄａｐａ）化合物
WO2020157570A1 (en) 2019-01-31 2020-08-06 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
WO2020160464A1 (en) * 2019-02-01 2020-08-06 Marshall University Research Corporation Transient receptor potential melastatin 8 (trpm8) antagonists and related methods
WO2021195256A1 (en) * 2020-03-24 2021-09-30 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
US20220087997A1 (en) * 2020-09-22 2022-03-24 Fertin Pharma A/S Oral Antagonist Compositions For Nicotine Burning Relief
WO2022105986A1 (de) * 2020-11-17 2022-05-27 Symrise Ag Neue kühlstoffe und zubereitungen, die diese enthalten
US12397518B2 (en) * 2021-04-29 2025-08-26 Coopervision International Limited WS12-releasing contact lens
WO2022257981A1 (zh) * 2021-06-08 2022-12-15 广州岐微生物医药科技有限公司 化合物在抑制或杀灭螨虫及治疗干眼症中的应用
IL313616A (en) * 2021-12-17 2024-08-01 Aerie Pharmaceuticals Inc Ophthalmic pharmaceutical compositions and uses thereof
US20230350228A1 (en) 2022-04-28 2023-11-02 Coopervision International Limited Contact lens
GB2629125B (en) 2022-10-31 2025-06-25 Coopervision Int Ltd WS12-releasing contact lens
WO2024220876A1 (en) * 2023-04-19 2024-10-24 Alcon Inc. N-substituted c6 cyclyl carboxamide compounds and uses thereof
TW202534349A (zh) 2023-10-27 2025-09-01 英商庫博光學國際有限公司 隱形眼鏡

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57179121A (en) 1981-04-27 1982-11-04 Showa Kagaku Kogyo Kk Remedy for oculopathy
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
JPH1067684A (ja) * 1996-06-17 1998-03-10 Mitsubishi Chem Corp 涙液分泌促進剤
HUP9904697A3 (en) 1996-10-11 2001-06-28 Bristol Myers Squibb Company P Methods and compositions for immunomodulation
CN1199617A (zh) 1996-12-18 1998-11-25 虎发光 一种治疗眼病的中成药
JPH10236972A (ja) * 1997-02-28 1998-09-08 Mitsubishi Chem Corp 涙液分泌促進剤
JP4591728B2 (ja) * 1998-12-28 2010-12-01 大正製薬株式会社 眼精疲労改善用点眼剤
JP3142842B1 (ja) * 1999-10-22 2001-03-07 ライオン株式会社 眼科用組成物及びソフトコンタクトレンズへの吸着抑制方法
AU1731101A (en) * 1999-12-07 2001-06-18 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US7651686B2 (en) 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
WO2003064602A2 (en) * 2002-01-25 2003-08-07 The Regents Of The University Of California Methods of modulating cold sensory perception
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
BR0311337A (pt) 2002-05-28 2005-03-15 Altana Pharma Ag Uso oftalmológico de roflumilast para o tratamento de doenças do olho
JP2005536511A (ja) 2002-07-15 2005-12-02 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ ４−１ｂｂ結合物質を用いる治療及び予防
EP1539237A4 (en) 2002-07-30 2006-05-24 Bristol Myers Squibb Co HUMANIZED ANTIBODIES AGAINST HUMAN 4-1BB
IL152486A0 (en) * 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
DE10259619A1 (de) * 2002-12-18 2004-07-08 Metagen Pharmaceuticals Gmbh Verwendung einer TRPM8 aktivierenden Substanz zur Tumorbehandlung
JP4601265B2 (ja) * 2003-05-14 2010-12-22 ロート製薬株式会社 局所適用製剤
CA2530884C (en) * 2003-07-02 2016-01-12 Genentech, Inc. Trp-p8 active compounds and therapeutic treatment methods
CN1565501A (zh) 2003-07-08 2005-01-19 毛友昌 明目地黄新的制备工艺及其制剂
US20050137166A1 (en) * 2003-12-19 2005-06-23 Alcon, Inc. Use of cooling agents to relieve mild ocular irritation and enhance comfort
WO2006040136A1 (en) 2004-10-13 2006-04-20 Bayer Healthcare Ag Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonists for the treatment of urological disorder
WO2006062731A1 (en) * 2004-11-19 2006-06-15 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
JP5078254B2 (ja) * 2004-12-17 2012-11-21 ロート製薬株式会社 眼科用組成物
EP2399935A3 (en) 2005-02-15 2012-02-22 GTC Biotherapeutics, Inc. An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
GB0504194D0 (en) * 2005-03-02 2005-04-06 Givaudan Sa Organic compounds
WO2007017092A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
CN1775261A (zh) 2005-11-18 2006-05-24 北京阜康仁生物制药科技有限公司 明目地黄制剂及新的制备方法
CN1775263A (zh) 2005-11-18 2006-05-24 北京阜康仁生物制药科技有限公司 杞菊地黄制剂及新的制备方法
US7727516B2 (en) * 2006-02-28 2010-06-01 The Procter & Gamble Company Reduction of hair growth
RU2305517C1 (ru) 2006-03-09 2007-09-10 Сергей Васильевич Широков Способ лечения эпифоры
WO2007108541A1 (ja) * 2006-03-23 2007-09-27 Senju Pharmaceutical Co., Ltd. キサンタンガムおよびブドウ糖を含有する眼科用組成物
WO2008066644A1 (en) 2006-11-02 2008-06-05 Riolan Technologies, Inc. Methods of treating epiphora
GB2451503B (en) * 2007-08-01 2011-10-12 Lrc Products Stimulating gel comprising a cyclic carboxamide coolant
CN101612199A (zh) 2008-06-28 2009-12-30 孙斌 治疗眼睛红肿和遇风流泪的冲洗液
FR2934778B1 (fr) * 2008-08-11 2012-09-28 Natura Cosmeticos Sa Compositions d'anti-transpirants et procedes permettant de reduire la transpiration chez les humains
US8653099B2 (en) * 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
ES2377785B2 (es) * 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.

Also Published As

Publication number Publication date
WO2012032209A2 (es) 2012-03-15
US10028920B2 (en) 2018-07-24
US20150313854A1 (en) 2015-11-05
US20130245231A1 (en) 2013-09-19
JP2019131621A (ja) 2019-08-08
JP2025172101A (ja) 2025-11-20
EP2614860A4 (en) 2014-01-29
WO2012032209A3 (es) 2012-07-12
EP2614860A2 (en) 2013-07-17
US20170071875A1 (en) 2017-03-16
US9901549B2 (en) 2018-02-27
US20170049728A1 (en) 2017-02-23
JP2021107422A (ja) 2021-07-29
EP4268814A2 (en) 2023-11-01
JP2024069452A (ja) 2024-05-21
US9433679B2 (en) 2016-09-06
ES2377785A1 (es) 2012-04-02
JP2017036298A (ja) 2017-02-16
US9095609B2 (en) 2015-08-04
EP4268814A3 (en) 2024-01-24
JP2013537887A (ja) 2013-10-07

Similar Documents

Publication Publication Date Title
ES2377785B2 (es) Composición farmacéutica para el tratamiento del ojo seco.
US8455504B2 (en) Inhibition of the activity of the capsaicin receptor in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance or insulin resistance
JP6173298B2 (ja) 治療薬としての肝細胞増殖因子模倣体
BR112014022708B1 (pt) Uso de uma proteína ligante de neurotrofina p75ntr e composição farmacêutica
WO2001087335A2 (en) Method for selectively inhibiting ghrelin action
US20030211967A1 (en) Method for selectively inhibiting ghrelin action
ES2389314T3 (es) Uso de antagonistas de IL-1 para tratar la gota y la pseudogota
TW200916112A (en) The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
Iwase et al. Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit
Xie et al. MLN4924 inhibits hedgehog signaling pathway and activates autophagy to alleviate mouse laser-induced choroidal neovascularization lesion
BRPI0620242A2 (pt) combinação compreendendo a combretastatina e agentes anti-cancerìgenos
JP6698358B2 (ja) 汗分泌促進剤及び該汗分泌促進剤を含有するドライスキンの予防薬又は治療薬
CN101879151A (zh) 大黄素在制备p2x3介导神经病理痛/神经系统疾病药物中的应用
ES2408132B1 (es) Composición farmacéutica para el tratamiento de la epífora.
US6348488B1 (en) Remedies for motor dysfunction and GAPDH expression inhibitors
WO2024142211A1 (ja) 認知症治療薬
US20200237715A1 (en) COX-2 Inhibitors for the Treatment of Ocular Disease
HK1205693B (en) Therapeutic use of p75ntr neurotrophin binding protein
WO2011054993A1 (es) Péptidos para el tratamiento de la hipertensión ocular y/o el glaucoma

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2377785

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20120926

GD2A Contractual licences

Effective date: 20191219